Cabometyx

Cabometyx (cabozantinib), supplied by VuRoyal (SuQian) Pharmaceutical Company LLC, is a targeted, multi-kinase-inhibitor anti-tumor therapy used for advanced renal cell carcinoma, hepatocellular carcinoma, and radioactive-iodine-refractory differentiated thyroid cancer, working by blocking tumor angiogenesis and growth through inhibition of multiple tyrosine kinases. Common side effects include hypertension, hand-foot skin reaction, diarrhea, and abnormal liver function; it is contraindicated in pregnancy, requires regular monitoring of blood pressure, liver, kidney, and heart function, and interacts with foods such as grapefruit that affect drug metabolism. The supplier does not manufacture it directly, and it is distributed across North America, Central/South America, and Western and Eastern Europe.